Patient Assistance Program for Adcetris® in Malaysia

To enable eligible patients in Malaysia to complete their course of treatment with Adcetris® even if they cannot afford to pay for it in full. Adcetris is indicated for the treatment of relapased and refractory Hodgkin's lymphoma (RR HL) and relapsed and refractory systemic anaplastic large cell lymphoma (RR sALCL).

This patient assistance program enables eligible Malaysian patients to complete their course of treatment with Adcetris®, even if they cannot afford to pay for it in full. It is adapted to Malaysia's mixed system of private and public care, and has been developed with the agreement of the government of Malaysia. It is based on a confidential means-based assessement, conducted by an independent, third party organization, that determines how many vials of treatment the patient will need to pay for, and how many will be covered by Takeda and other parties.

Before the launch of Adcetris® there were no treatment options for Malaysian patients with RR HL or RR sALCL.

The program's ultimate goal is to optimize care and treatment benefits, and reduce the burden of RR HL and RR sALCL in Malaysia in terms of its impact on quality of life and mortality in a way that is sustainable over the long term.

Partnership information

Company(ies) Takeda

Partner(s) Axios International

Type of Partner(s) Other Business

Therapeutic Focus Non-Communicable Diseases

Disease(s) Cancer

Program Type(s) Availability of Treatment - Financial Support

Region(s) East Asia & Pacific

Number of Countries 1

Country(ies) Malaysia

Start Date 2017

Anticipated completion date Ongoing